Activation of the NF-κB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy
- 14 February 2011
- journal article
- retracted article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (9), 3743-3748
- https://doi.org/10.1073/pnas.1012753108
Abstract
Because our in silico analysis with a human transcription factor database demonstrated the presence of several binding sites for NF-κB, a central regulator of cellular immune and inflammatory responses, in the adeno-associated virus (AAV) genome, we investigated whether AAV uses NF-κB during its life cycle. We used small molecule modulators of NF-κB in HeLa cells transduced with recombinant AAV vectors. VP16, an NF-κB activator, augmented AAV vector-mediated transgene expression up to 25-fold. Of the two NF-κB inhibitors, Bay11, which blocks both the canonical and the alternative NF-κB pathways, totally ablated transgene expression, whereas pyrrolidone dithiocarbamate, which interferes with the classical NF-κB pathway, had no effect. Western blot analyses confirmed the abundance of the nuclear p52 protein component of the alternative NF-κB pathway in the presence of VP16, which was ablated by Bay11, suggesting that AAV transduction activates the alternative NF-κB pathway. In vivo, hepatic AAV gene transfer activated the canonical NF-κB pathway within 2 h, resulting in expression of proinflammatory cytokines and chemokines (likely reflecting the sensing of viral particles by antigen-presenting cells), whereas the alternative pathway was activated by 9 h. Bay11 effectively blocked activation of both pathways without interfering with long-term transgene expression while eliminating proinflammatory cytokine expression. These studies suggest that transient immunosuppression with NF-κB inhibitors before transduction with AAV vectors should lead to a dampened immune response, which has significant implications in the optimal use of AAV vectors in human gene therapy.This publication has 53 references indexed in Scilit:
- High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed TyrosinesMolecular Therapy, 2010
- Directed Evolution of a Novel Adeno-associated Virus (AAV) Vector That Crosses the Seizure-compromised Blood–Brain Barrier (BBB)Molecular Therapy, 2010
- Proteasome Inhibitors Decrease AAV2 Capsid derived Peptide Epitope Presentation on MHC Class I Following TransductionMolecular Therapy, 2010
- Mitochondrial dynamics regulate the RIG‐I‐like receptor antiviral pathwayEMBO Reports, 2009
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008
- Induction of a pro-apoptotic ATM–NF-κB pathway and its repression by ATR in response to replication stressThe EMBO Journal, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvantProceedings of the National Academy of Sciences, 2006
- Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammationBritish Journal of Pharmacology, 2002